Shares of TRANSTHERA-B (02617) surged by more than 14% during the trading session. At the time of writing, the stock is up 8.87%, trading at HK$34.38.
Recently, TRANSTHERA-B (02617) announced the completion of a share placement on May 27, 2026. The placing agent successfully allotted a total of 3.84 million new H shares at a price of HK$40.83 per share to no fewer than six placees.
The gross proceeds from this placement amount to approximately HK$157 million. After deducting placing commissions and other related expenses, the net proceeds are about HK$152 million, resulting in a net issue price of roughly HK$39.66 per share. The company intends to allocate around 90% of the net proceeds, or approximately HK$137 million, towards the development of new indications for its core product, Tinengotinib. The remaining 10%, or about HK$15.21 million, will be used for working capital and general corporate purposes. Following the completion of the placement, the company's shareholding structure has been adjusted, with specific details outlined in the announcement.
Comments